Avita Medical sees positive results from burns trial

Company News

by Jessica Amir

Avita Medical Limited (ASX:AVH) has achieved positive results from its 30 patient trial in treating severe burns.

The regenerative medical company will submit the data from the successful trial of its skin harvesting device, ReCell, to the US Food and Drug Administration for Premarket Approval (PMA).

Avita Medical says it’s expecting US commercialization to occur before Q2 2018.

The company says the device will significantly advance burn care in the US.

Shares in Avita Medical Limited (ASX:AVH) are trading 5.88% higher to 9 cents.
 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?